title: Influence of apolipoprotein E polymorphism on serum lipid and lipoprotein changes: a 21-year follow-up study from childhood to adulthood. The Cardiovascular Risk in Young Finns Study.
abstract: BACKGROUND
  We examined the influence of apolipoprotein E (apoE) polymorphism on longitudinal changes in serum lipids by following the subjects participating in The Cardiovascular Risk in Young Finns Study over a 21-year period.
  
  
  METHODS
  Serum lipids were determined in randomly selected Finnish children and adolescents in 1980 and the subjects were re-examined in 1983, 1986 and after 21 years in 2001. ApoE polymorphism was determined in 1736 participants, and serum lipid values and apoE phenotypes were available for 1233 subjects.
  
  
  RESULTS
  ApoE phenotype-related differences in serum total and low-density lipoprotein (LDL)-cholesterol were maintained throughout the 21-year follow-up from childhood to adulthood, i.e., the apoE epsilon2 allele was consistently associated with lower and the epsilon4 allele with higher total and LDL-cholesterol (p<0.001 for all). In adulthood, there was also a significant apoE phenotype-related difference in high-density lipoprotein (HDL)-cholesterol (p=0.007), and the epsilon2 allele was associated with higher and the epsilon4 allele with lower apoA-I and HDL-cholesterol. In addition, apoB increased in the phenotype order E3/2<E3/3<E4 (E4/3+E4/4) (p<0.001). The LDL-lowering effect of the epsilon2 allele was greater in adulthood than in childhood, i.e., there was a significant apoE phenotypextime interaction (p=0.039) with longitudinal change in LDL-cholesterol.
  
  
  CONCLUSIONS
  ApoE polymorphism is associated with lipid levels at different ages and affects the longitudinal change in LDL-cholesterol from childhood to adulthood.
authors.affiliation: Laboratory of Atherosclerosis Genetics, Department of Clinical Chemistry, Tampere University Hospital, Medical School at the University of Tampere, Tampere, Finland. paula.gronroos@tyks.fi
authors.forename: Paula
authors.initials: P
authors.lastname: Grönroos
authors.forename: Olli T
authors.initials: OT
authors.lastname: Raitakari
authors.forename: Mika
authors.initials: M
authors.lastname: Kähönen
authors.forename: Nina
authors.initials: N
authors.lastname: Hutri-Kähönen
authors.forename: Jukka
authors.initials: J
authors.lastname: Marniemi
authors.forename: Jorma
authors.initials: J
authors.lastname: Viikari
authors.forename: Terho
authors.initials: T
authors.lastname: Lehtimäki
mesh_terms: D000293:Adolescent; D000328:Adult; D053329:Apolipoprotein E2 / Q000097:blood; D053327:Apolipoprotein E4 / Q000097:blood; D001057:Apolipoproteins E / Q000235:genetics*; D002318:Cardiovascular Diseases; D002648:Child; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005387:Finland / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008137:Longitudinal Studies; D011110:Polymorphism, Genetic; D012306:Risk
chemical_list: D053329:Apolipoprotein E2; D053327:Apolipoprotein E4; D001057:Apolipoproteins E; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D008055:Lipids; D008074:Lipoproteins